Commencement of fixed dose ICS of varying particle size as a predictor of pneumonia in COPD patients

David Price; William  Henley; Victoria Carter; Derek Skinner; Rebecca  Vella; Alberto Papi; Leonardo M Fabbri; Huib AM  Kerstjens; Nicolas Roche; Dave  Singh; Claus F Vogelmeier; Elif  Şen; José Eduardo  Delfini Cançado; Maxim  Kots; Elena  Nudo; Sara  Barile; George  Georges

Commencement of fixed dose ICS of varying particle size as a predictor of pneumonia in COPD patients

David Price, William Henley, Victoria Carter, Derek Skinner, Rebecca Vella, Alberto Papi, Leonardo M Fabbri, Huib AM Kerstjens, Nicolas Roche, Dave Singh, Claus F Vogelmeier, Elif Şen, José Eduardo Delfini Cançado, Maxim Kots, Elena Nudo, Sara Barile, George Georges

Research output: Contribution to conference › Oral Presentation/ Invited Talk

2 Downloads (Pure)

Abstract

Demographic and clinical characteristics have been used to identify predictive risk factors for pneumonia development in COPD patients. The present investigation extended this modelling to include commencing pharmacological therapies as a variable.

Original language	English
Publication status	Accepted/In press - 22 Dec 2022
Event	Annual Scientific Meetings of The Australia and New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand - Te Pae Christchurch Convention Centre, Christchurch, New Zealand Duration: 25 Mar 2023 → 28 Mar 2023 https://www.tsanzsrsasm.com/

Conference

Conference	Annual Scientific Meetings of The Australia and New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand
Abbreviated title	TSANZSRS 2023
Country/Territory	New Zealand
City	Christchurch
Period	25/03/23 → 28/03/23
Internet address	https://www.tsanzsrsasm.com/

Bibliographical note

Grant Support:
This study was funded by Chiesi Farmaceutici S.p.A.

David Price has grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Theravance and UK National Health Service; is a peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline.

Keywords

particle size
ICS
pneumonia
COPD
extrafine

Access to Document

Price_Abstract_Commencement_fixed_doseAccepted author manuscript, 312 KBLicence: Unspecified

Cite this

Price, D., Henley, W., Carter, V., Skinner, D., Vella, R., Papi, A., Fabbri, L. M., Kerstjens, H. AM., Roche, N., Singh, D., Vogelmeier, C. F., Şen, E., Delfini Cançado, J. E., Kots, M., Nudo, E., Barile, S., & Georges, G. (Accepted/In press). Commencement of fixed dose ICS of varying particle size as a predictor of pneumonia in COPD patients. Annual Scientific Meetings of The Australia and New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand, Christchurch, New Zealand.

Commencement of fixed dose ICS of varying particle size as a predictor of pneumonia in COPD patients. / Price, David; Henley, William ; Carter, Victoria et al.
2022. Annual Scientific Meetings of The Australia and New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand, Christchurch, New Zealand.

Research output: Contribution to conference › Oral Presentation/ Invited Talk

Price, D, Henley, W, Carter, V, Skinner, D, Vella, R, Papi, A, Fabbri, LM, Kerstjens, HAM, Roche, N, Singh, D, Vogelmeier, CF, Şen, E, Delfini Cançado, JE, Kots, M, Nudo, E, Barile, S & Georges, G 2022, 'Commencement of fixed dose ICS of varying particle size as a predictor of pneumonia in COPD patients', Annual Scientific Meetings of The Australia and New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand, Christchurch, New Zealand, 25/03/23 - 28/03/23.

@conference{a98063f0b09d42699c2eee3699cd5758,

title = "Commencement of fixed dose ICS of varying particle size as a predictor of pneumonia in COPD patients",

abstract = "Demographic and clinical characteristics have been used to identify predictive risk factors for pneumonia development in COPD patients. The present investigation extended this modelling to include commencing pharmacological therapies as a variable.",

keywords = "particle size, ICS, pneumonia, COPD, extrafine",

author = "David Price and William Henley and Victoria Carter and Derek Skinner and Rebecca Vella and Alberto Papi and Fabbri, {Leonardo M} and Kerstjens, {Huib AM} and Nicolas Roche and Dave Singh and Vogelmeier, {Claus F} and Elif {\c S}en and {Delfini Can{\c c}ado}, {Jos{\'e} Eduardo} and Maxim Kots and Elena Nudo and Sara Barile and George Georges",

note = "Grant Support: This study was funded by Chiesi Farmaceutici S.p.A. David Price has grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Theravance and UK National Health Service; is a peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline. ; Annual Scientific Meetings of The Australia and New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand, TSANZSRS 2023 ; Conference date: 25-03-2023 Through 28-03-2023",

year = "2022",

month = dec,

day = "22",

language = "English",

url = "https://www.tsanzsrsasm.com/",

}

TY - CONF

T1 - Commencement of fixed dose ICS of varying particle size as a predictor of pneumonia in COPD patients

AU - Price, David

AU - Henley, William

AU - Carter, Victoria

AU - Skinner, Derek

AU - Vella, Rebecca

AU - Papi, Alberto

AU - Fabbri, Leonardo M

AU - Kerstjens, Huib AM

AU - Roche, Nicolas

AU - Singh, Dave

AU - Vogelmeier, Claus F

AU - Şen, Elif

AU - Delfini Cançado, José Eduardo

AU - Kots, Maxim

AU - Nudo, Elena

AU - Barile, Sara

AU - Georges, George

N1 - Grant Support: This study was funded by Chiesi Farmaceutici S.p.A. David Price has grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Theravance and UK National Health Service; is a peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline.

PY - 2022/12/22

Y1 - 2022/12/22

N2 - Demographic and clinical characteristics have been used to identify predictive risk factors for pneumonia development in COPD patients. The present investigation extended this modelling to include commencing pharmacological therapies as a variable.

AB - Demographic and clinical characteristics have been used to identify predictive risk factors for pneumonia development in COPD patients. The present investigation extended this modelling to include commencing pharmacological therapies as a variable.

KW - particle size

KW - ICS

KW - pneumonia

KW - COPD

KW - extrafine

M3 - Oral Presentation/ Invited Talk

T2 - Annual Scientific Meetings of The Australia and New Zealand Society of Respiratory Science and The Thoracic Society of Australia and New Zealand

Y2 - 25 March 2023 through 28 March 2023

ER -

Commencement of fixed dose ICS of varying particle size as a predictor of pneumonia in COPD patients

Abstract

Conference

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this